File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1126/stke.3812007pe14
- Scopus: eid_2-s2.0-34648876684
- PMID: 17426345
Supplementary
- Citations:
- Appears in Collections:
Article: Metabolic targeting as an anticancer strategy: dawn of a new era?
Title | Metabolic targeting as an anticancer strategy: dawn of a new era? |
---|---|
Authors | |
Issue Date | 2007 |
Citation | Science's STKE, 2007, v. 2007, n. 381, article no. pe14 How to Cite? |
Abstract | As a result of a spectrum of mitochondrial defects, tumor cells often preferentially use glycolysis to generate adenosine triphosphate (ATP), even in the presence of oxygen, a phenomenon known as aerobic glycolysis, or the "Warburg effect." Dichloroacetate (DCA) is an inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase (PDH), a gatekeeping enzyme for the entry of pyruvate into the mitochondrial tricarboxylic acid (TCA) cycle. In mice, DCA treatment appears to reactivate mitochondrial respiration in tumor cells, induces their selective killing, and suppresses cancer growth. These observations provide intriguing insights into the plasticity of tumor metabolism that may offer new opportunities for therapeutic intervention. |
Persistent Identifier | http://hdl.handle.net/10722/291787 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pan, James G. | - |
dc.contributor.author | Mak, Tak W. | - |
dc.date.accessioned | 2020-11-17T14:55:07Z | - |
dc.date.available | 2020-11-17T14:55:07Z | - |
dc.date.issued | 2007 | - |
dc.identifier.citation | Science's STKE, 2007, v. 2007, n. 381, article no. pe14 | - |
dc.identifier.uri | http://hdl.handle.net/10722/291787 | - |
dc.description.abstract | As a result of a spectrum of mitochondrial defects, tumor cells often preferentially use glycolysis to generate adenosine triphosphate (ATP), even in the presence of oxygen, a phenomenon known as aerobic glycolysis, or the "Warburg effect." Dichloroacetate (DCA) is an inhibitor of mitochondrial pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase (PDH), a gatekeeping enzyme for the entry of pyruvate into the mitochondrial tricarboxylic acid (TCA) cycle. In mice, DCA treatment appears to reactivate mitochondrial respiration in tumor cells, induces their selective killing, and suppresses cancer growth. These observations provide intriguing insights into the plasticity of tumor metabolism that may offer new opportunities for therapeutic intervention. | - |
dc.language | eng | - |
dc.relation.ispartof | Science's STKE | - |
dc.title | Metabolic targeting as an anticancer strategy: dawn of a new era? | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1126/stke.3812007pe14 | - |
dc.identifier.pmid | 17426345 | - |
dc.identifier.scopus | eid_2-s2.0-34648876684 | - |
dc.identifier.volume | 2007 | - |
dc.identifier.issue | 381 | - |
dc.identifier.spage | article no. pe14 | - |
dc.identifier.epage | article no. pe14 | - |
dc.identifier.eissn | 1525-8882 | - |
dc.identifier.issnl | 1525-8882 | - |